A clinical analysis of primary testicular diffuse large B-cell lymphoma in China

Figures & data

Table 1. Clinical characteristics

Characteristic	No. of patients	%
Age (years)
Median	57
Range	22–83
B symptoms
Absent	29	90·625
Present	3	9·375
Location
Left	13	40·625
Right	19	59·375
Bilateral	0
Serum LDH
Normal	17	53·125
Elevated	6	18·75
Unknown	9	28·125
ECOG score
0–1	26	81·25
2–4	6	18·75
IPI
0–1	21	65·625
⩾2	9	28·125
Unknown	2	6·25
Stage
I	23	71·875
II	7	21·875
III	2	6·25
IV	0

Note: LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index.

Table 2. Patient characteristics and treatment modalities and outcomes

Patient no.	Age (years)	Location	Stage	B symptoms	IPI	Surgery	Further therapy	Chemotherapy (cycles)	Response	Time to relapse (months)	Site of relapse	Overall survival (months)
1	61	Left	I		na	Uni	Chemo+RTp	6 CHOP-like	CR	176·10	CNS	254·13+
2	55	Left	I		Low	Uni	Chemo	4 CHOP-like	CR	11·17	Te	53·33+
3	29	Right	I		Low	Uni	Chemo+RTp+ITC	3 CHOP-like+4 R-CHOP-like	CR			35·03+
4	80	Left	I		High	Uni	Chemo	3 CHOP-like	ne			3
5	52	Right	I		Low	Uni	No		CR			25·9+
6	68	Right	I		Low	Uni	Chemo+ITC	3 CHOP-like	ne			45·23+
7	57	Right	I		Low	Uni	Chemo	4 R-CHOP-like+2 CHOP-like	CR			48·33+
8	57	Left	II		Low	Uni	Chemo	6 CHOP-like	CR			70·9+
9	45	Right	II		Low	Uni	Chemo	6 CHOP-like	PD	6·43	Skin of chest	37·17+
10	53	Left	I	Night sweats	Low	Uni	No		CR	1·97	CNS	48·77
11	70	Left	I	Night sweats	High	Uni	Chemo+RTp	6 CHOP-like	CR	10·13	Te	20·33
12	51	Right	II		High	Uni	Chemo+ITC	8 CHOP-like	CR			89·63+
13	73	Left	I		Low	Uni	Chemo	1 CHOP-like+5 R-CHOP-like	CR			85·77+
14	77	Right	I		High	Uni	Chemo	6 CHOP-like	CR			82·83+
15	79	Left	I		High	Uni	No		CR			30·73
16	61	Right	I		Low	Uni	Chemo+RTp	6 CHOP-like	CR			73·57+
17	46	Right	III		High	Uni		6 CHOP-like	CR			66+
18	58	Right	I		Low	Uni	Chemo+RTp	4 CHOP-like	CR	74·67	Left neck+CNS	81·13
19	43	Right	I		Low	Uni	Chemo	6 CHOP-like	CR			193·33+
20	45	Right	I		Low	Uni	Chemo+RTp	4 CHOP-like	CR	8·17	Nasopharynx+Te	115·2+
21	50	Left	II		High	Uni	Chemo+RTp	6 CHOP-like	CR	32·17	?	35·47
22	52	Right	I		Low	Uni	Chemo	4 CHOP-like	CR			38·1+
23	83	Right	I		Low	Uni	No		CR	31·47	Te+nasopharynx+CNS	49·97
24	66	Left	I		Low	Uni	Chemo+RTp+ITC	6 R-CHOP-like	CR			49·03+
25	40	Right	II		Low	Uni	Chemo+ITC	7 CHOP-like	CR			26·17+
26	22	Right	I		Low	Uni	Chemo+ITC	4 R-CHOP-like+2 CH0P-like	CR			20·27+
27	56	Left	II	Fever and night sweats	Low	Uni	Chemo+RTn	6 CHOP-like	PR	22·30	Soft tissue+CNS+vertebrae	131·4+
28	76	Right	I		High	Uni		6 CHOP-like	CR			66·5+
29	43	Right	I		Low	Uni		6 R-CHOP-like	CR	16·23	CNS	17·47+
30	61	Left	I		na	Uni		6 CHOP-like	CR	7·13	Lung	10·2
31	78	Right	III		High	Uni	No		SD			38·1+
32	47	Left	II		Low	Uni	Chemo+ITC	6 CHOP-like	CR	27·27	CNS	53·17+

Note: IPI, International Prognostic Index; na = not available; Uni = unilateral orchidectomy; Te = contralateral testis; ne = no evaluation; IT = intrathecal prophylaxis; RTp = prophylactic radiation; RTn = nodal radiotherapy; SD, stable disease; ? = unknown; CHOP-like/R-CHOP-like = see text; Relapse = relapse after CR (complete remission), PD (progressive disease) and progression after PR (partial remission); CNS, central nervous system.

Figure 1. Kaplan–Meier estimate of progression-free survival and overall survival for patients.

Table 3. Univariate analysis of prognostic factors for PFS and OS

	P value (log-rank test)
	PFS	OS
Age (years)	0·732	0·184
⩽60
>60
B symptoms	0·001	0·142
Absent
Present
ECOG score	0·001	0·000
0–1
2–4
Stage	0·997	0·268
I
II–IV
LDH	0·774	0·457
Normal
Elevated
IPI	0·87	0·09
0–1
2–5
Extranodal site other than testis	0·523	0·933
Yes
No
Location	0·012	0·045
Left
Right
Both
Lymph node involvement at diagnosis	0·558	NA
Yes
No
First relapse time	0·000	0·066
>1 year
<1 year
CNS involvement	0·029	0·414
Yes
No
Post-orchiectomy treatment	0·34	0·026
Yes
No
Chemotherapy (cycles)	0·474	0·072
<4
⩾4
Rituximab	0·209	NA
Yes
No
Prophylactic intrathecal chemotherapy	0·144	NA
Yes
No
Prophylactic radiotherapy	0·759	0·566
Yes
No

Note: bold entries indicate that the P value is less than 0.05. PFS, progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index; CNS, central nervous system.